Dynogen Pharmaceuticals Report issue

For profit Phase 2 Phase 3
Founded: Boston MA United States (2002)
Status: Acquired by Astellas (2006) → now Leo Pharma (2015)

Organization Overview

First Clinical Trial
2005
NCT00215566
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2007

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Dynogen Pharmaceuticals, Inc

Active Ingredients

Drugs in Phase 3 Trials (1)

pumosetrag (2 trials)

Drugs in Phase 2 Trials (1)

ddp225 (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Constipation (Phase 3)

Diarrhea (Phase 2)

Irritable Bowel Syndrome (Phase 3)

Syndrome (Phase 3)

Vomiting (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 2